Repare Therapeutics Inc. (RPTX)

In December 2025, Gilead Sciences, Inc. acquired Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467, for up to $30 million, including a $25 million upfront payment, leading to an 18% surge in RPTX stock. In November 2025, Repare Therapeutics announced a definitive agreement to be acquired by XenoTherapeutics, Inc., with shareholders expected to receive an estimated $1.82 per share in cash at closing, plus one non-transferable contingent value right (CVR) per common share, causing the stock to surge 26% in after-hours trading. Also in November 2025, the company reported its third-quarter 2025 financial results, with revenue from collaboration agreements of $11.6 million and a net income of $3.3 million. In October 2025, Repare presented initial topline safety, tolerability, and early efficacy data from its Phase 1 LIONS clinical trial for RP-1664. In July 2025, Repare entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. for lunresertib, receiving a $10 million upfront payment and eligibility for up to $257 million in potential milestones and single-digit royalties. In May 2025, Repare out-licensed its early-stage discovery platforms to DCx Biotherapeutics Corporation, including a $1 million upfront payment, $3 million in near-term payments, and a 9.99% equity position in DCx. In March 2025, Repare announced a re-alignment of resources and a re-prioritization of its clinical portfolio, including a workforce reduction of approximately 75% to extend its cash runway into late 2027.

Information regarding demand seasonality for Repare Therapeutics, Inc.'s products and services is not publicly available in the provided search results.

Repare Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing novel therapeutics that target genomic instability, including DNA damage repair, utilizing its proprietary SNIPRx® platform. The company's core business revolves around developing highly targeted cancer therapies, with key product candidates including Camonsertib (RP-3500), Lunresertib (RP-6306), RP-1664, and RP-3467. Repare Therapeutics also engages in strategic collaborations with various pharmaceutical companies.

Repare Therapeutics conducts its discovery and development activities in Switzerland and the United States and is headquartered in Montreal, Canada.

Repare Therapeutics' reputation has been tied to its clinical advancements, financial performance, and strategic corporate actions, with mixed analyst sentiment. The announcement of the acquisition by XenoTherapeutics in November 2025 led to an investigation by a class action firm, but the company's CEO stated that the transaction was in the best interests of Repare and its stakeholders.

Repare Therapeutics' stock ownership is a mix of institutional, retail, and individual investors, with approximately 56.56% held by Institutional Investors, 1.45% by Insiders, and 41.99% by Public Companies and Individual Investors. Major institutional shareholders include Bvf Inc/il, Blue Owl Capital Holdings LP, Orbimed Advisors Llc, Versant Venture Management, LLC, Redmile Group, LLC, Mpm Asset Management Llc, MPM Oncology Impact Management LP, Renaissance Technologies Llc, Citadel Advisors Llc, and Rangeley Capital, LLC. Among individual investors, Brad Bolzon owns the most shares.